1Ramirez J A, Mgayen T.Treating community-acqured pneumonia with once- daily gatifloxacin VS twice-daily clarithromycin. J Respir Dis, 1999, 20:s60-69.
2Forrest A, Nix DE,Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993, 37:1073-1081
3Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis , 1998, 27:33-39.
4Dalnoff A. Pharmacodymics of fluoquinolones. J Antimicrob Chemother, 1999, 43:51-59.
5Ruiz-Gonzalez A, Falguera M,Nogues A, et al. Is streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia.Am J Med, 1999, 106:385-390.
6Niederman MS, Mandell LA, Anzueto A, et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med, 2001,163:1730-1754.
7Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. J Antimicrob Chemother, 1999, 43 Supple C:83-90.
8DeAbate CA, Russell M, et al. Safety and efficacy if oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care, 1999, 42:206-213.
9Ramirez A, Molina J, et al. Gatifloxacin treatment in patients with acute exacerbation of chronic bronchitis: clinical trial results. J Respir Dis, 1999, 20: S 30-39.
10File TM Jr, Segreti J, Dunbar L,et al. A multi-center, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired penumonia, Antimicrob Agents Chemother, 1997, 41:1965-1972.
